Clinical outcomes in patients with early non-small-cell lung cancer treated surgically in Bogota (Colombia)

被引:0
|
作者
Alvarado-Sarzosa, Fernando [1 ]
Martinez-Jaramillo, Stella Isabel [2 ,3 ]
Hellal, Luis Gerardo Garcia-Herreros- [4 ]
Beltran-Jimenez, Rafael Jose [5 ]
Zuluaga-Restrepo, Juan David [6 ]
Parra-Medina, Rafael [7 ]
Escobar-avila, Laura Lucia [8 ]
Toledo-Arenas, Jose Daniel [9 ]
Carvajal-Fierro, Carlos Andres [5 ]
机构
[1] Univ Bosque, Programa Posgrad Cirugia Torax, Inst Nacl Cancerol, Convenio Docencia Serv, Bogota, DC, Colombia
[2] Cirugia Torax, Clin Reina Sofia, Bogota, DC, Colombia
[3] Univ Bosque, Programa Especializac Cirugia Torax, Bogota, DC, Colombia
[4] Fdn Santa Fe Bogota, Cirugia Torax, Bogota, DC, Colombia
[5] Inst Nacl Cancerol, Unidad Func Cirugia Torax, Bogota, DC, Colombia
[6] Clin CES, Cirugia Torax, Medellin, Colombia
[7] Inst Nacl Cancerol, Grp Patol Oncol, Bogota, DC, Colombia
[8] Lab Patol, Clin Reina Sofia, Bogota, DC, Colombia
[9] Univ Bosque, Psiquiatria & Epidemiol, , D C, Bogota, DC, Colombia
来源
REVISTA COLOMBIANA DE CANCEROLOGIA | 2023年 / 27卷 / 02期
关键词
Carcinoma; non-small-cell lung; adenocarcinoma of lung; neoplasm staging; recurrence; VISCERAL PLEURAL INVASION; INTERNATIONAL ASSOCIATION; GRADING SYSTEM; AIR SPACES; CLASSIFICATION; ADENOCARCINOMA; RECURRENCE; EPIDEMIOLOGY; REVISION; PROPOSAL;
D O I
10.35509/01239015.904
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: In Colombia, information is limited on the survival of patients with lung cancer treated in the early stages. Thus, this study aimed to analyze the clinical outcomes and factors associated with the prognosis of patients with non-small-cell lung cancer (NSCLC) treated surgically in three institutions in Bogota.Methods: Analytical, observational, retrospective, and multicenter study.Results: The study included 101 patients with a median age of 69 years (IQR 63-75); 56 were women (55.4%). Of the patients, 8 (7.9%) had pathological stage 0, 83 (82.2%) were in stage I and 10 (9.9%) in stage II. The 3-year disease-free survival (DFS) of patients with stages 0, I, and II was 100%, 97%, and 58%, respectively. The overall survival (OS) of all included patients at 3 years was 94%. The OS of patients with and without relapse was 78% and 96%. A statistically significant association was found between relapse and stage II (P<0.001), relapse and T3 (P=0.048), relapse and N1 (P<0.001), and relapse and visceral pleura invasion (P=0.002). The only association found with death was relapse (P=0.002).Conclusions: The pathological stage and some special TNM characteristics, such as T3 tumor, the presence of N1 disease, and visceral pleura invasion, were determining factors in DFS. In contrast, the only factor associated with worse OS was relapse.
引用
收藏
页码:240 / 250
页数:11
相关论文
共 50 条
  • [1] CLINICAL OUTCOMES IN PATIENTS WITH NON-SMALL-CELL LUNG CANCER TREATED IN PHASE I CLINICAL TRIALS
    Janku, F.
    Gong, J.
    Garrido-Laguna, I.
    Parsons, H. A.
    Vaklavas, C.
    Kurzrock, R.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : S86 - S86
  • [2] Survival outcomes in patients with non-small-cell lung cancer treated with erlotinib
    McGrath, Alexandria C.
    Sandhu, Geeta
    Walpole, Euan
    McCaffrey, Elizabeth
    Hollingworth, Samantha A.
    ANTI-CANCER DRUGS, 2018, 29 (08) : 786 - 790
  • [3] Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab
    Facchinetti, Francesco
    Veneziani, Michele
    Buti, Sebastiano
    Gelsomino, Francesco
    Squadrilli, Anna
    Bordi, Paola
    Bersanelli, Melissa
    Cosenza, Agnese
    Ferri, Leonarda
    Rapacchi, Elena
    Mazzaschi, Giulia
    Leonardi, Francesco
    Quaini, Federico
    Ardizzoni, Andrea
    Missale, Gabriele
    Tiseo, Marcello
    IMMUNOTHERAPY, 2018, 10 (08) : 681 - 694
  • [4] Clinical Outcomes In Patients With Non-Small-Cell Lung Cancer With Leptomeningeal Carcinomatosis
    Takahashi, Y.
    Moriguchi, S.
    Ogawa, K.
    Murase, K.
    Mochizuki, S.
    Hanada, S.
    Uruga, H.
    Miyamoto, A.
    Takaya, H.
    Morokawa, N.
    Kurosaki, A.
    Fujii, T.
    Kishi, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [5] Sarcopenia: an unneglectable nutritional status for patients with surgically treated non-small-cell lung cancer Reply
    Sun, Changbo
    Anraku, Masaki
    Nakajima, Jun
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2019, 56 (02) : 420 - 421
  • [6] Treatment of Surgically Resectable Non-Small-Cell Lung Cancer in Elderly Patients
    Haithcock, Benjamin E.
    Stinchcombe, Thomas E.
    Socinski, Mark A.
    CLINICAL LUNG CANCER, 2009, 10 (06) : 405 - 409
  • [7] Does sarcopenia have any impact on survival of patients with surgically treated non-small-cell lung cancer?
    Deng, Han-Yu
    Zha, Panpan
    Hou, Liang
    Huang, Kai-Li
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2019, 29 (01) : 144 - 147
  • [8] Surgical outcomes of non-small-cell lung carcinoma in patients previously treated for gastric cancer
    Tsubokawa, Norifumi
    Mimae, Takahiro
    Aokage, Keiju
    Hattori, Aritoshi
    Suzuki, Kenji
    Nagai, Kanji
    Tsuboi, Masahiro
    Okada, Morihito
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2015, 47 (04) : 648 - 652
  • [9] Validation of the Eighth Edition of the TNM Staging System for Lung Cancer in 2043 Surgically Treated Patients With Non-small-cell Lung Cancer
    Chen, Kezhong
    Chen, Haiqing
    Yang, Fan
    Sui, Xizhao
    Li, Xiao
    Wang, Jun
    CLINICAL LUNG CANCER, 2017, 18 (06) : E457 - E466
  • [10] Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib
    Liu, G.
    Gurubhagavatula, S.
    Zhou, W.
    Wang, Z.
    Yeap, B. Y.
    Asomaning, K.
    Su, L.
    Heist, R.
    Lynch, T. J.
    Christiani, D. C.
    PHARMACOGENOMICS JOURNAL, 2008, 8 (02): : 129 - 138